DiaMedica Therapeutics Inc. (NASDAQ:DMAC) has scheduled a conference call for 5th November 2020 at 8:00 AM Eastern Time to announce its 3Q20 financial results.
The company released its quarterly earnings, after the market close on Wednesday 4th November 2020
The conference call will also be webcast live under the investor relations section of the website www.diamedica.com
Earnings Expectation
DiaMedica Therapeutics Inc. is reporting third quarter earnings results on Wednesday 4th November 2020, after market close.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of recombinant proteins for the treatment of kidney and neurological diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company is also developing DM199 for the treatment vascular dementia; and DMDx, a diagnostic tool to measure human tissue kallikrein-1 levels.
